PRESS RELEASE

Sanofi Pasteur's Typhoid Vaccine, Typhim Vi®, Granted Prequalification by the World Health Organization

- Designation will facilitate global access to vaccine for the prevention of typhoid fever in the most vulnerable populations around the world -

Lyon, France - June 23, 2011 - Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that the World Health Organization (WHO) has granted prequalification to its Typhim Vi® polysaccharide typhoid vaccine. Typhim Vi® is the first WHO prequalified typhoid vaccine.

WHO prequalification is a key step that allows for the procurement of vaccines by UNICEF and other United Nations (UN) agencies like the Pan American Health Organization (PAHO) Revolving Fund. It is also a prerequisite for GAVI Alliance New and Underused Vaccines Support for vaccine distribution, ensuring and improving developing countries' access to vaccines that meet unified standards of quality, safety and efficacy.

"In line with our ambition to provide the best vaccines at affordable prices to developing countries, Sanofi Pasteur is truly pleased and proud to bring to the immunization community the first WHO-prequalified typhoid vaccine, Typhim Vi®, to help combat a serious disease that affects the lives of millions of individuals each year particularly in the most impoverished countries," said Olivier Charmeil, President and CEO of Sanofi Pasteur.

As a dedicated, longstanding contributor to public health, Sanofi Pasteur collaborates with global heath authorities and international organizations, including GAVI, UNICEF and WHO, committed to controlling and preventing enteric and other infectious diseases. Through these collaborations, Sanofi Pasteur aims at sharing its strong R&D, industrial and logistical expertise, know-how and experience in vaccines, and at providing the developing countries with full support to introduce typhoid vaccination in their national immunization programs to prevent childhood typhoid fever in endemic regions.

Sanofi Pasteur is also a member of the Coalition against Typhoid (CaT), a global forum of typhoid immunization experts hosted by the Sabin Vaccine Institute, whose goal is to identify the barriers to the adoption of typhoid vaccine and the key activities needed for these barriers to be broken down. *"WHO prequalification of a typhoid vaccine is a crucial step towards universal access and the use of these vaccines where they are needed most,*" confirmed Ciro De Quadros, MD MPH, Executive Vice President at the Sabin Vaccine Institute.

In addition, Sanofi Pasteur is a key partner in the Vi-based Vaccines for Asia (VIVA) initiative of the International Vaccine Institute (IVI), a Seoul, Korea-based international organization, on pilot typhoid vaccine introduction programs to provide resources and technical support to assist authorities in defining optimal disease control strategies in the countries and regions where typhoid fever is an important public health issue affecting, in particular, the children in the poorest populations.

Typhim Vi® polysaccharide typhoid vaccine is licensed in over 100 countries and is indicated for active immunization of persons two years of age and older against typhoid fever. First licensed in 1988 in France, Typhim Vi® vaccine, manufactured at Sanofi Pasteur's facility in Marcy L'Etoile, France, has established a longstanding safety and seroprotection track record.

About Typhoid Fever

Typhoid fever is a bacterial disease, caused by *Salmonella enterica* serovar Typhi (*Salmonella* Typhi). It is transmitted through the ingestion of food or drink contaminated by the faeces or urine of infected people. Symptoms usually develop 1–3 weeks after exposure, and may be mild or severe. They include fever, malaise, headache, constipation or diarrhoea, rose-coloured spots on the chest, and enlarged spleen and liver. Healthy carrier state (persisting for month or years) may follow acute illness. Typhoid fever can be treated with antibiotics. However, resistance to common antimicrobials is widespread. Healthy carriers should be excluded from handling food.
http://www.who.int/topics/typhoid_fever/en/

Typhoid fever is a major cause of morbidity with an estimated global incidence of approximately 21 million cases each year. According to one conservative estimate, there were approximately 216,000 deaths from typhoid worldwide in the year 2000.
http://www.ivi.int/program/tr_domi_typhoid.html

About WHO Prequalification Process

WHO prequalification is a regulatory step aimed at ensuring that diagnostics, medicines and vaccines for high-burden diseases meet global standards of quality, safety and efficacy, in order to optimize use of health resources and improve health outcomes.

The prequalification process consists of a transparent, scientifically sound assessment, which includes dossier review, consistency testing or performance evaluation and site visits to manufacturers. This information, in conjunction with other procurement criteria, is used by UN and other procurement agencies to make purchasing decisions regarding diagnostics, medicines and/or vaccines.
http://www.who.int/topics/prequalification/en/

About Typhim Vi® Vaccine

http://www.who.int/immunization_standards/vaccine_quality/pq_238_typhoid_20dose_sanofi_pasteur/en/index.html

About GAVI Alliance New and Underused Vaccine Support

http://www.gavialliance.org/support/index.php

About the International Vaccine Institute (IVI)

http://www.ivi.org/

About the Coalition Against Typhoid

http://www.sabin.org/advocacy-education/coalition-against-typhoid

About Vi-based Vaccines for Asia (VIVA) initiative

http://viva.ivi.int/TyphoidInformationCenter/Forresearchers.html

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development. For more information, please visit: www.sanofipasteur.com or www.sanofipasteur.us

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2010. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Contacts:

Global Media Relations
Pascal Barollier
T. +33-(0)4-37-37-50-38
pascal.barollier@sanofipasteur.com
www.sanofipasteur.com